MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

MDT

96.14

-0.57%↓

A

136.19

-1%↓

VEEV

223.11

-0.69%↓

HQY

91.51

-0.5%↓

PHR.US

16.9

-0.59%↓

Search

Schrodinger Inc

Cerrado

SectorSanidad

17.81 0.23

Resumen

Variación precio

24h

Actual

Mínimo

17.71

Máximo

17.86

Métricas clave

By Trading Economics

Ingresos

10M

-33M

Ventas

-435K

54M

Margen de beneficios

-60.369

Empleados

891

EBITDA

10M

-31M

Recomendaciones

By TipRanks

Recomendaciones

Compra Fuerte

Estimación a 12 Meses

+45.41% upside

Estadísticas de Mercado

By TradingEconomics

Capitalización Mercado

-198M

1.3B

Apertura anterior

17.58

Cierre anterior

17.81

Noticias sobre sentimiento de mercado

By Acuity

50%

50%

141 / 374 Clasificación en Healthcare

Puntuación técnica

By Trading Central

Confianza

Very Strong Bearish Evidence

Schrodinger Inc Gráfico

Resultados pasados no son un indicador fiable de resultados futuros.

Noticias Relacionadas

31 dic 2025, 22:20 UTC

Principales Movimientos del Mercado

Outlook Therapeutics Shares Fall After Another FDA Rejection of Macular Degeneration Drug

31 dic 2025, 17:31 UTC

Principales Movimientos del Mercado

OwlTing Climbs on Launch of $10 Million Stock-Buyback Program

31 dic 2025, 16:30 UTC

Principales Movimientos del Mercado

Trump Media Gains on Plan to Distribute Digital Tokens to Shareholders

31 dic 2025, 15:19 UTC

Principales Movimientos del Mercado

Axsome Shares Climb on FDA Fast‑Track for Alzheimer's Drug, Backing for Narcolepsy Filing

31 dic 2025, 15:17 UTC

Principales Movimientos del Mercado

Nike Shares Rise After CEO Hill Buys $1 Million of Shares

31 dic 2025, 14:37 UTC

Principales Movimientos del Mercado

Corcept Shares Fall as FDA Requires More Evidence for Hypercortisolism Drug Application

1 ene 2026, 23:35 UTC

Charlas de Mercado

Gold Rises Amid Geopolitical Risks -- Market Talk

1 ene 2026, 21:29 UTC

Adquisiciones, fusiones, absorciones

BlueScope: Transaction Completed on Terms Agreed When Deal Announced on Nov 13

1 ene 2026, 21:29 UTC

Adquisiciones, fusiones, absorciones

BlueScope Sold Stake in JV to Tata Steel

1 ene 2026, 21:28 UTC

Adquisiciones, fusiones, absorciones

BlueScope Steel Says Sale of Stake in Tata BlueScope Steel Completed on Dec 31

1 ene 2026, 17:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

1 ene 2026, 09:20 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

31 dic 2025, 21:50 UTC

Charlas de Mercado

Basic Materials Roundup: Market Talk

31 dic 2025, 21:13 UTC

Adquisiciones, fusiones, absorciones

10 People to Watch in Wealth Management in 2026 -- Barrons.com

31 dic 2025, 20:40 UTC

Charlas de Mercado

Dollar Posting Its Worst Year Since 2017 -- Market Talk

31 dic 2025, 20:22 UTC

Charlas de Mercado

Oil Posts Loss in a Year Marked By Plentiful Supply -- Market Talk

31 dic 2025, 19:50 UTC

Charlas de Mercado

U.S. Natural Gas Futures Sink on Weather Outlook -- Market Talk

31 dic 2025, 19:31 UTC

Charlas de Mercado

Precious Metals Cap Off Record Runs -- Market Talk

31 dic 2025, 18:50 UTC

Charlas de Mercado

Global Equities Roundup: Market Talk

31 dic 2025, 18:50 UTC

Charlas de Mercado

Canadian Gold Miners Enjoy a Bumper Year in 2025 -- Market Talk

31 dic 2025, 17:17 UTC

Charlas de Mercado

U.S. Natural Gas Inventories Fall Less Than Expected -- Market Talk

31 dic 2025, 17:16 UTC

Principales Movimientos del Mercado

OwlTing Climbs on Launch of $10M Stock-Buyback Program

31 dic 2025, 17:15 UTC

Charlas de Mercado

Global Commodities Roundup: Market Talk

31 dic 2025, 17:00 UTC

Adquisiciones, fusiones, absorciones

Nvidia Is Getting Creative as Options to Use Its Cash Flood Narrow -- Heard on the Street -- WSJ

31 dic 2025, 15:57 UTC

Adquisiciones, fusiones, absorciones

Vanda Pharmaceuticals Shares Jump 30% on Motion Sickness Drug Approval -- Barrons.com

31 dic 2025, 15:54 UTC

Charlas de Mercado

Layoff Data Supports Dollar at End of Losing Year -- Market Talk

31 dic 2025, 15:02 UTC

Principales Movimientos del Mercado

Nike Shares Rise After CEO Hill Buys $1M of Shares

31 dic 2025, 14:40 UTC

Adquisiciones, fusiones, absorciones

Nike CEO Buys $1 Million of Stock as Insiders Bet on a Turnaround -- Barrons.com

31 dic 2025, 14:20 UTC

Charlas de Mercado

Crude Futures On Track to End the Year With Losses -- Market Talk

31 dic 2025, 13:46 UTC

Charlas de Mercado

U.S. Natural Gas Falls on Milder Weather Outlook -- Market Talk

Comparación entre iguales

Cambio de precio

Schrodinger Inc previsión

Precio Objetivo

By TipRanks

45.41% repunte

Estimación a 12 Meses

Media 26 USD  45.41%

Máximo 33 USD

Mínimo 21 USD

De acuerdo con 6 analistas de Wall Street que ofrecen objetivos de precios a 12 meses para Schrodinger Inc Dist en los últimos 3 meses.

Consenso

By TipRanks

Compra Fuerte

6 ratings

5

Comprar

1

Mantener

0

Vender

Puntuación técnica

By Trading Central

23.27 / 26.13Soporte y Resistencia

Corto Plazo

Very Strong Bearish Evidence

Medio plazo

Very Strong Bullish Evidence

Largo Plazo

Very Strong Bullish Evidence

Sentimiento

By Acuity

141 / 374 Clasificación en Sanidad

Noticias sobre sentimiento de mercado

Neutral

Volatilidad

Por debajo de la media

Volumen de Noticias (RCV)

Por debajo de la media

Finanzas

Gastos de venta y administración

Gastos operativos

Beneficio antes de impuestos

Ventas

Coste de ventas

Beneficio bruto de ventas

Gasto por intereses de deuda

EBITDA

Beneficio operativo

$

Acerca de Schrodinger Inc

Schrödinger, Inc., together with its subsidiaries, develops physics-based computational platform that enables discovery of novel molecules for drug development and materials applications. The company operates in two segments, Software and Drug Discovery. The Software segment is focused on licensing its software to transform molecular discovery for life sciences and materials science industries. The Drug Discovery segment focuses on building a portfolio of preclinical and clinical programs, internally and through collaborations. The company serves biopharmaceutical and industrial companies, academic institutions, and government laboratories worldwide. It has a research collaboration and license agreement with Novartis AG to advance multiple development candidates. Schrödinger, Inc. was incorporated in 1990 and is based in New York, New York.
help-icon Live chat